Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Cash & Equivalents: 2021-2024

Historic Cash & Equivalents for LifeStance Health (LFST) over the last 4 years, with FY2024 value amounting to $154.6 million.

  • LifeStance Health's Cash & Equivalents rose 9870.68% to $203.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.9 million, marking a year-over-year increase of 9870.68%. This contributed to the annual value of $154.6 million for FY2024, which is 9609.64% up from last year.
  • LifeStance Health's Cash & Equivalents amounted to $154.6 million in FY2024, which was up 9609.64% from $78.8 million recorded in FY2023.
  • LifeStance Health's Cash & Equivalents' 5-year high stood at $154.6 million during FY2024, with a 5-year trough of $78.8 million in FY2023.
  • For the 4-year period, LifeStance Health's Cash & Equivalents averaged around $122.5 million, with its median value being $128.3 million (2021).
  • In the last 5 years, LifeStance Health's Cash & Equivalents tumbled by 2743.21% in 2023 and then soared by 9609.64% in 2024.
  • Over the past 4 years, LifeStance Health's Cash & Equivalents (Annual) stood at $148.0 million in 2021, then fell by 26.62% to $108.6 million in 2022, then dropped by 27.43% to $78.8 million in 2023, then skyrocketed by 96.1% to $154.6 million in 2024.
  • Its Cash & Equivalents stands at $154.6 million for FY2024, versus $78.8 million for FY2023 and $108.6 million for FY2022.